Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you elaborate on the 100 to 200 basis points adjusted EBITDA margin improvement expected for 2025? A: Joe Busky, CFO: The improvement is primarily driven by the $100 million in annualized cost savings, with $20 million realized in the first half of 2025. Additional cost-saving initiatives are underway across procurement, IT, and other areas. However, we also anticipate a 3% merit increase for employees and normal inflation, which could impact margins. The timing of the 2024-2025 respiratory season could also affect margins.
Q: How predictable is the demand for consumables in the labs business, and what is the outlook for Q4 and 2025? A: Joe Busky, CFO: The labs business has good visibility due to five to seven-year contracts and predictable ordering patterns. We expect mid-single-digit growth in this business, with some variability due to timing between quarters.
Q: What are the expectations for the respiratory season, given the early start last year and the summer spike this year? A: Joe Busky, CFO: We are assuming a typical flu season with a 30% year-over-year decline in respiratory revenue for Q4. We are cautious about the timing of revenues, which could shift to Q1 2025. The COVID-19 revenue is expected to be in the range of $160 to $170 million for the full year.
Q: Can you provide more details on the organizational changes and their impact on the company? A: Brian Blazer, CEO: We eliminated the Chief Commercial Officer and COO roles to flatten the organization, improve speed and efficiency, and get closer to customers. The changes are at the top level and have no impact on customer-facing roles. We have strong leaders in place who will now report directly to me.
Q: What is the outlook for the China market, considering the cardiac reimbursement pressures and potential stimulus benefits? A: Joe Busky, CFO: We expect high single-digit growth in China for 2024 and mid to high single-digit growth for 2025. While there are potential headwinds from value-based pricing and anti-corruption policies, the Chinese government's economic stimulus plan could be a tailwind. We are monitoring the situation closely.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。